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Background: Under-carboxylated osteocalcin (ucOC), the precursor substrate of bone biomarker OC is a potent
regulator of energy metabolism by promoting insulin production and adiponectin synthesis and decreasing fat
stores. The aim of the present study was to point out the potential role of ucOC in the physiopathology of
polycystic ovary syndrome (PCOS), a common disorder defined by the constellation of anovulation,
insulinresistance, hyperinsulinemia, obesity and androgen excess.
Methods: In this prospective case–control investigation, 78 young premenopausal women, i.e. 52 PCOS patients
and 26 age- and body mass index (BMI)-matched healthy controls, were successively enrolled. Recruitment of PCOS
patients was performed according to Androgen Excess-Polycystic Ovary Syndrome (AE-PCOS) Society 2006 criteria.
All study participants were subjected to clinical examination, whole-body composition assessment and
measurements of serum ucOC, OC (1-49), glucose and lipids, insulin, total testosterone (TT), estradiol, sex-hormone
binding globulin (SHBG), high-sensitivity C-reactive protein (Hs-CRP) and β-CrossLaps.
Results: BMI-stratified multivariate analysis revealed significantly higher ucOC levels in PCOS vs. controls in lean
(p = 0.001) but not overweight and obese study participants (p = 0.456). Notably, a positive correlation between
ucOC and TT (p = 0.018), calculated free testosterone (cFT, p = 0.028) and serum insulin (p = 0.036), respectively,
was found to be confined to the lean analysis subgroup. Furthermore, in stepwise multiple regression models,
β-CrossLaps and cFT were able to predict 46.71% of serum ucOC variability. (1-43/49)OC failed to be significantly
associated to any PCOS trait.
Conclusions: Circulating ucOC concentration is related to key endocrine PCOS characteristics in a
weight-dependent manner. Within the bone-pancreas loop, high ucOC may favor insulin release in lean
hyperandrogenic women to compensate for impaired insulin sensitivity.
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Osteocalcin (OC), a traditional osteoblast-/odontoblast-
secreted biomarker, is synthesized as under-carboxylated
precursor molecule and further processed by posttran-
slational vitamin K-dependent γ-glutamylcarboxylation
to deliver the mature, carboxylated bone matrix-bound
protein. Apart from reasonable evidence of association
to low bone mass [1] and subsequent fracture risk [2],
circulating OC in its under-carboxylated form (ucOC)
was recently acknowledged as one missing clue in the
endocrine cross-talk between the skeleton and energy
metabolism. Groundbreaking studies revealed that ucOC
may impact glucose metabolism control by stimulating
expression of several ß-cell proliferation genes [3] and
promoting expression of the insulin gene and increasing
insulin production within ß-cells [4]. Hence, ucOC acts
as an insulin secretagogue. In addition to that, ucOC
may positively control energy metabolism through the
release of adiponectin, an insulin-mimetic adipocytokine,
from fat cells [3]. In turn, both OC gene expression and
OC decarboxylation in osteoblast-like cells are up-regu-
lated by insulin receptor signaling via osteoprotegerin
(OPG)/ligand of receptor activator of nuclear factor kappa
B (RANKL) pathway [5].
Notably, an extracellular/circulating γ-decarboxylase
to convert carboxylated OC into ucOC is not described
yet. Therefore, it is suggested that the skeleton repre-
sents the primary source of ucOC. In fact, serum ucOC
results on one hand from osteoblastic cell secretion and
on the other hand from decarboxylation of matrix-bound
carboxylated OC through resorption of bone. More re-
cently, the adipose tissue was recognized as an OC and
ucOC source and ucOC release in the human adipose tis-
sue culture medium was confirmed [6].
Recent studies specifically analyzed the levels of circu-
lating OC gene products in relation to metabolic para-
meters in human showing significant relationships of
OC or ucOC to body mass index (BMI), body fat, gly-
cemic status and HbA1c in adult diabetic [7] and non-
diabetic subjects [8,9] even in prospectively planned
analyses [10]. Short-term (i.e. 3 months) changes in
serum ucOC levels in women on anti-fracture therapy for
postmenopausal osteoporosis on either anti-catabolic or
osteo-anabolic therapy correlate positively to the twelve-
months variations in body weight, body fat mass and
serum adiponectin, another evidence linking ucOC levels
to major metabolic indices [11].
Polycystic ovary syndrome (PCOS) represents the main
androgen excess disorder in women of reproductive age,
exhibiting polymorph phenotypes and coexistence of obe-
sity and/or insulin resistance in up to 50% of cases [12].
Nevertheless, the intimate mechanism of inappropriate glu-
cose metabolism control in these women remains incom-
pletely defined. Reports focused on androgen hormoneadministration in lean female-to-male transsexuals suggest
that insulin resistance in the hyper-androgenic women can-
not be attributed solely to androgen excess despite evidence
of visceral fat accumulation [13]. Additionally, both obese
and non-obese phenotypes of PCOS women may develop
impaired insulin sensitivity [14,15], oxidative stress [16] and
even endothelial injury [17-19].
The novel description of OC as a metabolic marker
raised the question of its potential implication in the pa-
thogenesis of PCOS. In one previous study, significantly
higher carboxylated OC (cOC) concentration was repor-
ted in patients with PCOS compared to controls thus
suggesting a potential relationship between PCOS status
and dynamics of the OC γ-carboxylation process [20].
Moreover, cOC and OC displayed by PCOS patients in
that study correlated with several PCOS endocrine and
metabolic components. In this prospective and cross-
sectional survey, circulating ucOC levels were directly
assayed for the first time in PCOS patients using a dedi-
cated two monoclonal antibodies ELISA. The relation-
ships of serum ucOC concentrations to body fat, serum
androgens, hyperinsulinism and low-grade inflammation
were investigated.
Methods
Between January 2009 and June 2010, 78 Caucasian
women (52 patients with PCOS and 26 healthy controls,
aged 24.620 ± 0.688 years) were successively recruited
and managed on an outpatient basis at a tertiary en-
docrine care center. Androgen Excess-Polycystic Ovary
Syndrome (AE-PCOS) Society 2006 Task Force diagnos-
tic criteria for PCOS were employed and patients with
hirsutism (= or >8 on the Ferriman-Gallwey scoring sys-
tem) and/or biochemical hyperandrogenism, and oligo-
anovulation (history of no more than 8 spontaneous
menses in the previous year) and/or polycystic ovaries
(>12 follicles 2–9 mm diameter and/or ovarian vol-
ume >10 cm3 on ultrasound) were enrolled. Subjects
with confirmed androgen-secreting tumors, congenital
adrenal hyperplasia and Cushing’s syndrome, hyperprolac-
tinemia or thyroid disease as well as current or previous
(within 6 months) use of oral contraceptives, metformin,
glitazones, statins, anti-androgens, infertility medication
or drugs known to affect the carbohydrate-lipid metab-
olism were excluded. A control group of age- and BMI-
matched eugonadal women without clinical and/or bio-
chemical evidence of hyperandrogenism was created and
all the aforementioned exclusion criteria were applied to
the control group. The study was conducted with the
approval of the local ethics committee on clinical inves-
tigations and informed consent was obtained from all
participants.
Careful physical examination of subjects was done and
data on height (cm), weight (kg), the Ferriman-Gallwey
Table 1 Main study parameters assessed in PCOS patients
and healthy eugonadal women (n = 78)
PCOS (n = 52) Controls (n = 26)
Age (years) 24.44 ± 5.49 25.96 ± 7.28
BMI (kg/m2) 28.79 ± 5.66 27.03 ± 6.04
WHR 0.85 ± 0.06 0.79 ± 0.06**
Total body FM (kg) 32.94 ± 11.58 28.79 ± 11.49
SBP (mm Hg) 108.46 ± 12.46 107.88 ± 12.66
DBP (mm Hg) 72.01 ± 9.96 70.38 ± 9.26
ucOC (ng/ml) 3.11 ± 0.68 2.79 ± 0.84#
OC (ng/ml) 13.76 ± 6.58 13.07 ± 6.55
β-CrossLaps (ng/ml) 0.539 ± 0.426 0.528 ± 0.334
TT (nmol/l) 3.04 ± 1.20 1.91 ± 0.80***
cFT (nmol/l) 0.051 ± 0.027 0.020 ± 0.012***
SHBG (nmol/l) 47.58 ± 32.09 88.03 ± 41.19***
Glucose (mg/dl) 85.57 ± 7.90 84.53 ± 7.03
Insulin (μU/ml) 16.56 ± 6.83 12.40 ± 3.81*
HOMA-IR 3.54 ± 1.64 2.60 ± 0.87**
QUICKI 0.322 ± 0.020 0.334 ± 0.017*
Hs-CRP (mg/l) 5.51 ± 3.91 4.04 ± 3.87
Results are presented as mean ± SD and compared by Mann Whitney or
two-tailed independent t-test, as appropriated. Abbreviations: BMI, body mass
index, WHR, waist-to-hip ratio, FM, fat mass, SBP, systolic blood pressure, DBP,
diastolic blood pressure, ucOC, under-carboxylated osteocalcin, OC, (1-43/49)
osteocalcin, TT, total testosterone, cFT, calculated free testosterone, SHBG, sex
hormone-binding globulin, HOMA-IR, homeostasis model assessment for
insulin resistance, QUICKI, quantitative insulin sensitivity check index, Hs-CRP,
high sensitivity C-reactive protein. *p < 0.05, **p < 0.01, ***p < 0.001, #p = 0.070
and p = 0.016 after adjusting for total body fat mass.
Pepene Journal of Ovarian Research 2013, 6:4 Page 3 of 8
http://www.ovarianresearch.com/content/6/1/4score and blood pressure (mm Hg) was recorded in each
study participant. The body mass index was calculated
as weight (kilograms) divided by height (meters) squared
(kg/m2). Body mass index (BMI) cutoff between lean
and overweight and obese individuals was considered
25 kg/m2. Systolic blood pressure (SBP) and diastolic
blood pressure (DBP) were measured in the right arm,
with the subjects in a seated position. The average of two
measurements taken with a mercury sphygmomanometer
was used.
Employing the whole-body dual X-ray absorptiometry
technique using DPX-NT (GE, Madison, USA) equip-
ment, body composition parameters (i.e. total body fat
mass and total body fat-free mass) were determined in a
fasting state, during the same visit the blood samples
were collected. Quality control was ensured by constant
calibration using both the phantom provided by the ma-
nufacturer and the HOLOGIC 1540 phantom. The coef-
ficient of variance (CV), evaluated at 3% for total body
fat mass was determined by serial measurements on 10
patients, each one examined 3 times.
Blood samples were obtained between 08.00 and 10.00
a.m., after overnight fasting and during early follicular
phase of a spontaneous or dydrogesterone-induced men-
strual cycle. The serum obtained immediately after blood
collection was stored at −80°C until the time of assay.
Insulin, total testosterone (TT), sex hormone-binding glo-
bulin (SHBG), estradiol and high-sensitivity C-reactive
protein (Hs-CRP) were all measured using ELISA kits
from DRG Instruments, Marburg, Germany. According to
Vermeulen’s formula, calculated free testosterone (cFT)
was obtained from TT and SHBG serum concentration.
As in previous work [19], the cFT cutoff level was defined
as 0.028 nmol/l. Serum β-CrossLaps ELISA was purcha-
sed from Immunodiagnostic Systems Ltd, Boldon, UK.
Serum OC was quantitatively assayed using the Osteo-
calcin (1-43/49) ELISA kit from ALPCO Diagnostics,
Salem, NH, USA. The lowest detectable limit for OC
was 0.31 ng/ml and the mean intra-assay CV was 4.7%.
Duplicate serum ucOC concentrations were obtained by
a commercial two monoclonal antibodies ELISA from
Takara Bio Inc, Otsu, Japan. The mean intra-assay CV of
was 4.4%. The kit sensitivity was 0.5 ng/ml.
Statistical analysis
Data were expressed as mean ± SD. Continuous data
were compared using either the two-tailed t-test for
independent samples or the Mann–Whitney U-test, as
appropriate. Subgroup analysis of ucOC and OC after
stratifying by BMI was considered. Logarithmic transfor-
mations were performed as needed to ensure a normal
distribution of continuous variables. Associations of OC
to several variables were analyzed by univariate regres-
sion. The stepwise multiple regression analysis was usedto determine which variables predict serum ucOC levels
in the study population.
Results
Main endocrine and metabolic characteristics of study
participants and associations with OC and ucOC are de-
picted in Tables 1 and 2, respectively. A decline in circu-
lating OC forms with age (OC: r = −0.513, p < 0.0001
and ucOC: r = −0.481, p < 0.0001) was evident in the
entire cohort of premenopausal women. In addition, bi-
variate analysis revealed a highly significant inverse asso-
ciation of ucOC to BMI (r = −0.296, p = 0.008) and total
body fat mass (r = −0.300, p = 0.007), respectively. Like-
wise, a significant trend towards lower serum OC with
increasing BMI (r = −0.422, p = 0.0001) and fat mass
(r = −0.335, p = 0.002) was observed in the entire cohort.
Serum β-CrossLaps, a well-documented bone resorption
marker, significantly correlated with both OC (r = 0.456,
p < 0.0001) and ucOC (r = 0.450, p < 0.0001), respecti-
vely, a relationship not confounded by age and BMI for
ucOC (p = 0.034 in multivariate analysis).
In view of the abovementioned strong relationship bet-
ween various OC forms and body mass, study subjects
Table 2 Univariate regression analysis of serum OC with
endocrine and metabolic parameters, in PCOS and
controls
Serum OC Serum ucOC
PCOS Controls PCOS Controls
β β β β
Age (years) −1.159*** −1.535** −3.648*** −3.045*
BMI (kg/m2) −0.994** −1.359* −2.834** −2.595
Total body FM (g) −6.173e−6 * −1.067e−5 −2.068e−5* −2.550e−5
TT (nmol/l) 0.153 −0.173 0.563 −0.351
cFT (nmol/l) −0.005 0.020 0.230 −0.230
SHBG (nmol/l) 0.078 −0.215 −0.001 0.015
Glucose (mg/dl) 0.282 −0.358 −0.098 1.391
Insulin −0.198 0.223 −0.650 0.521
HOMA-IR −0.154 −0.214 −0.552 0.529
QUICKI 1.350 1.951 4.692 −5.120
β-CrossLaps (ng/ml) 0.408*** 0.450 1.238** 1.445*
Hs-CRP (mg/l) −0.068 −0.204* −0.312 −0.509
*p < 0.05; **p < 0.01; ***p < 0.001.
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n = 30) and overweight and obese (BMI ≥ 25 kg/m2,
n = 48) subgroups, respectively, and data analysis was
done accordingly. As illustrated in Figure 1, lean but
not overweight and obese patients with PCOS displayed
elevated serum ucOC levels in comparison to controls.
Furthermore, the weight-dependent behavior of ucOC
strengthened after adjustment for variations in age, body
fat mass and bone resorption rate, with a more apparent
difference in mean ucOC levels in lean (p = 0.001) but
still not significant in overweight and obese (p = 0.456)
PCOS patients vs. controls. Nonetheless, BMI-stratified
analysis failed to detect any significant differences in cir-
culating OC between PCOS patients and controls in
both simple and multivariate analysis (Figure 1).
As highlighted in Figure 2, higher serum ucOC was
associated in leaner women with higher serum TT
(β = 0.210, p = 0.018), cFT (β = 0.122, p = 0.028) and in-
sulin (β = 0.280, p = 0.036) whereas in overweight and
obese participants these associations were absent (TT:
β = 0.042, p = 0.675, FT: β = 0.081, p = 0.213, insulin:
β = 0.079, p = 0.516). In contrast, no relationships with
TT, cFT and insulin were evident for OC in either lean
(TT: β = 0.206, p = 0.232, cFT: β = 0.139, p = 0.196 and
insulin: β = 0.344, p = 0.182) or overweight and obese
participants in this study (TT: β = 0.068, p = 0.737, cFT:
β = 0.166, p = 0.209 and insulin: β = 0.061, p = 0.802).
In order to find out endocrine and metabolic deter-
minants of serum ucOC, stepwise multiple regression
models were established in lean study participants. There-
fore, ucOC was introduced as the dependent variable
in the model, whereas age, BMI, total body fat mass,β-CrossLaps and PCOS status were considered independ-
ent variables. The model (F = 13.885, p < 0.001) showed
that β-CrossLaps (p = 0.0006), PCOS status (p = 0.0009)
and age (p = 0.017) represented statistically significant de-
terminants of circulating ucOC concentrations. When free
testosterone and insulin replaced PCOS status, ucOC
was predicted only by β-CrossLaps (p = 0.0002) and cFT
(p = 0.003) in the model (F = 13.710, p < 0.001), meaning
that 46.71% of serum ucOC variability was explained by
these two parameters.
In the entire cohort, the inflammatory marker Hs-CRP
correlated with both OC (r = −0.295, p = 0.008) and ucOC
(r = −0.236, p = 0.037) but these associations were ren-
dered non-significant after controlling for fat mass.
Discussion
The study findings indicate that alterations in γ–
carboxylation of OC, in connection to weight status and
androgen hormones excess may depict PCOS. Participa-
tion of serum free testosterone as independent predictor
of ucOC, determining about half of ucOC variability
when corroborated to bone resorption rate, suggests
regulatory interrelationships between androgens and OC
metabolism in women, implying potential involvement
of the skeleton as an endocrine organ in the pathogen-
esis of PCOS. In addition to that, the positive association
of ucOC with serum insulin observed in lean study par-
ticipants is a finding which is in agreement to the key ef-
fect of ucOC to directly augment pancreatic insulin
production and delivery. In turn, within the bone-
pancreas regulatory loop, hyperinsulinemia, a feature of
PCOS, may promote bone matrix OC decarboxylation
and ucOC release via the OPG/RANKL pathway [5,21].
Nonetheless, the underlying mechanism linking ucOC
to androgen excess in PCOS is less clear. Human vis-
ceral adipose cells also express the OC gene, which ap-
pears to be up-regulated in vitro by dihydrotestosterone,
an effect which in men may be reflected by the positive
correlation of serum free testosterone with circulating
ucOC levels and the ucOC/OC ratio [22]. In male mouse
Leydig cells, the ability of osteoblastic ucOC to promote
testosterone gene expression at the transcriptional level
was recently acknowledged by Oury et al. [23] as an effect
accomplished via a G-protein coupled orphan receptor
which belongs to the C family of GCPRs expressed in
mice Leydig cells. Thus, a molecular basis was provided to
the positive association between serum OC and free tes-
tosterone levels observed in adult men or paralleling
skeletal growth in boys of pubertal age [24,25]. However,
mouse ovarian follicle cells appear not to express the OC
signaling pathway identified in Leydig cells and regulation
of sex steroids synthesis in the ovary by ucOC is not yet
demonstrated [23]. Notwithstanding, it has to be kept
in mind that in the study of Oury et al. testosterone
Figure 1 Body mass index-stratified analysis of osteocalcin (OC) in 52 cases and 26 age-matched controls. (upper panel). Higher
under-carboxylated (uc) OC concentration was evidenced in lean (p = 0.037) PCOS patients (n = 17, black bar) vs. controls (n = 13, blue bar) but
not overweight and obese (p = 0.490) PCOS patients (n = 35, black bar) vs. controls (n = 13, blue bar), even in multivariate analysis (p = 0.001 in
lean and p = 0.456 in overweight and obese). (lower panel). Statistical analysis retrieved no differences in serum OC in either lean (p = 0.146) or
overweight and obese (p = 0.569) women with PCOS (black bars) and controls (blue bars). Multivariate analysis had no effect on end results
(p = 0.535 in lean and p = 0.888 in overweight and obese).
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mice ovary explants, an experimental model not superpo-
sable to the physiopathological mechanisms governing an-
drogen regulation in PCOS.
Consistent with previous reports [9], both body mass
and body fat exerted a strong lowering effect on ucOC,
independently of the study subgroup. In fact, obvious
weight-dependent relationships of ucOC with several
endocrine and metabolic PCOS parameters became ap-
parent in the present study. While ucOC was positivelyrelated to both hyperandrogenemia and insulin concen-
tration in lean women, significant associations of ucOC
to PCOS traits lacked in the overweight and obese sub-
group pointing out to potential implication of additional
metabolic players affecting the relationship between ucOC
and endocrine parameters in PCOS. There is strong evi-
dence that leptin, one fat tissue-derived adipocytokine,
impairs OC production and bioactivity in the skeleton by
a central serotonin-mediated activation of the sympa-
thetic nervous system [26]. In mice, leptin up-regulates
Figure 2 Scatter plots and regression lines of ucOC association
to endocrine traits of study participants (n = 78). TT = total
testosterone, cFT = calculated free testosterone (●) lean women and
(○) overweight and obese women. (upper panel) (●) r = 0.430,
p =0.017 (○) r = 0.049, p = 0.740 (middle panel) (●) r = 0.402,
p = 0.027 (○) r = 0.181, p = 0.215 (lower panel) (●) r = 0.383
p = 0.036 (○) r = 0.081 p = 0.580.
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tase) gene expression via adrenergic β2 and ATF4 recep-
tors, an effect associated with accelerated γ-carboxylation
of OC, low ucOC and low insulin secretion and sensitivity
[27]. Although not assessed in the present study, one may
assume hyperleptinemia associated to increased fat mass
contributed to the lower OC and ucOC levels observed in
overweight and obese participants. In rats fed a high-fat
diet, obesity resulted in activation of PPAR (peroxisome
proliferator-activated receptor)-gamma and suppression of
Wnt/β-catenin pathways both associated with stimulation
of bone marrow adipogenesis and decreased osteoblast
differentiation, as a substrate to diminished OC concen-
tration [28]. Nevertheless, the relationship between OC
and fat mass appears to be reciprocal, since a decrease
in serum ucOC concentration induced by anti-catabolic
bone agents was able to predict long-term accumulation
of fat mass [11].
Likewise, in a population-based sample of healthy chil-
dren, ucOC was related to metabolic parameters in a
weight-dependent manner. Higher relative circulating
ucOC levels were associated to higher HOMA-IR in
leaner but not heavier subjects and to higher high mo-
lecular weight (HMW)-adiponectin concentration, an
association more apparent in heavier children [29], pre-
sumably in order to compensate for the low adiponectin
state in heavy subjects. Expression of adiponectin recep-
tors in osteoblasts and regulation of bone metabolism by
adiponectin both in vitro [30] and in vivo [31,32] in ad-
dition to increased adiponectin gene expression induced
by ucOC could support the concept of an adiponectin-OC
loop [3,29] and the increased ucOC delivery in response
to hypoadiponectinemia.
As shown here, serum OC assayed as both 1–49 OC
and the more stable N-mid (1–43) fragment rather poor-
ly reflects bone-energy metabolism axis status. In part,
this may be attributable to factors such as specificity of
the assay used, differences in pre-analytical sample sta-
bility or large intra-individual variations [33].
As a conclusion, in a weight-dependent manner, the
ucOC secretion pattern is related to PCOS status. In
lean women, high ucOC levels are strongly predicted by
testosterone excess and in turn, may contribute to in-
creased insulin secretion to compensate for altered insu-
lin sensitivity. Future studies are warranted to investigate
possible pathogenetic implications of ucOC in the devel-
opment of PCOS metabolic traits and its potential use-
fulness as a clinical tool.
Conclusions
Bone marker under-carboxylated osteocalcin (ucOC) ex-
hibits a weight-dependent pattern in patients with PCOS.
Circulating ucOC is predicted by androgen excess in lean
women and may stimulate compensatory insulin secretion
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presence of obesity.
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